Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.

Chemical biology & drug design - 1 Jan 2021

Smith Steven J, Pauly Gary T, Hewlett Katharine, Schneider Joel P, Hughes Stephen H

Abstract excerpt

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) inhibit reverse transcription and block the replication of HIV-1. Currently, NNRTIs are usually used as part of a three-drug combination given to patients as antiretroviral therapy. These combinations involve other classes of anti-HIV-1 drugs, commonly nucleoside reverse transcriptase inhibitors (NRTIs). However, attempts are being made to develop two-drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Drug Design

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Reverse Transcriptase

Share to Molecular Dynamics Simulation

Share to Pyridones

Share to Pyrimidines

Share to Rilpivirine

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 32743937
DOI: 10.1111/cbdd.13766
PMCID: PMC7821153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-based non-nucleoside inhibitor design: Developing inhibitors that are effective against resistant mutants.PMID 32743937Read ↗

Rilpivirine analogs potently inhibit drug-resistant HIV-1 mutants.Semantic proximity Read ↗

A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants.Semantic proximity Read ↗

Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase InhibitorsSemantic proximity Read ↗

Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.Semantic proximity Read ↗

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.Semantic proximity Read ↗

Structure-enhanced methods in the development of non-nucleoside inhibitors targeting HIV reverse transcriptase variants.Semantic proximity Read ↗

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.Semantic proximity Read ↗

Development of enhanced HIV-1 non-nucleoside reverse transcriptase inhibitors with improved resistance and pharmacokinetic profiles.Semantic proximity Read ↗

The Current Status of the NNRTI Family of Antiretrovirals Used Against HIV InfectionSemantic proximity Read ↗

Design Strategies of Novel NNRTIs to Overcome Drug ResistanceSemantic proximity Read ↗

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.Semantic proximity Read ↗

Rational Design of Potent Non-Nucleoside Inhibitors of HIV-1 Reverse TranscriptaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.